Affordable treatment for common man should be the focus of all drug discovery: Dr T Ramaswami
Affordable treatment for the common man should be the focus of any drug development and the important aspect to be considered while engaging in the discovery of drugs is the effective cure for diseases.
Affordable treatment for the common man should be the focus of any drug development and the important aspect to be considered while engaging in the discovery of drugs is the effective cure for diseases, said Dr T Ramaswami, Secretary, Department of Science and Technology (DST).
He was inaugurating the short term medicinal course for industrial and academic scientists at Sri Ramachandra University in Chennai.
“We also need a greater insight into chemical biology to bring about cure for diseases that can be affordable by people at large. Building collaborative excellence among industry, academia and research institutions to bring about ultimate benefit to patients is necessary. Government is giving the highest focus for public private partnership programmes in this regard,” he added.
Sri Ramachandra University and Orchid Chemicals and Pharmaceuticals signed an memorandum of understanding (MoU) on the occasion.
K Raghavendra Rao, CMD, Orchid Chemicals said India, which is now exporting generic drugs, is well on its way to invent new drugs and produce it for the world. The MoU, he said, will provide facility for students and faculty to have internship and knowledge development at Orchid Chemicals. Further, the scientists at the company will teach and share their knowledge with medicinal chemistry students and also collaborate in joint drug development, he added.
The International Conference on Medicinal Chemistry 2013 was organized by Sri Ramachandra University and sponsored by the Department of Science and Technology, American Chemical Society, The International Union of Pure and Applied Chemistry, USA.
Dr SP Thyagarajan, dean research who signed on behalf of SRU said the medicinal chemistry course for industrial and academic scientists is based on the success of Drew University Residential School on Medicinal Chemistry, USA. It will bring together leading industrial and academic experts to present lectures on key topics. Ten international resource persons, 90 scientists from pharma companies and 30 academicians participated in the conference, he said.
Dr Balu N Balasubramaniam from Pharma Innovation Sourcing Centre, USA expressed the hope that this new collaborative knowledge will result in valuable intellectual property in the near future.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.